Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | ACACA | Q13085 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909113 | 0.86 | EPHX2 (0.44) | EPHX2ACACBACACAALDH1A1EPHX1 | |
| SCHEMBL12313355 | 0.84 | MEN1 (0.54) | EPHX2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12452076 | 0.82 | MEN1 (0.56) | EPHX2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL22891629 | 0.82 | KDM4E (0.58) | EPHX2ACACBACACAALDH1A1MEN1 | |
| SCHEMBL3789686 | 0.81 | EPHX2 (0.46) | EPHX2ALDH1A1EPHX1MEN1KMT2A | |
| SCHEMBL18909112 | 0.81 | ACHE (0.51) | EPHX2ACACBACACAALDH1A1CHRM1 | |
| SCHEMBL21561085 | 0.81 | KDM4E (0.55) | EPHX2ACACBACACAALDH1A1CHRM1 | |
| SCHEMBL15932473 | 0.80 | ALDH1A1 (0.46) | EPHX2ACACBACACAALDH1A1KMT2A | |
| SCHEMBL18909232 | 0.79 | KDM4E (0.51) | EPHX2ALDH1A1CHRM1CHRM2KDM4E | |
| SCHEMBL21561140 | 0.78 | OPRM1 (0.44) | EPHX2ACACBACACAALDH1A1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3380474-B1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-08-21 | — | — | EP | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017089390-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | EPHX2 4091/4885ACACB 4301/4885ACACA 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.